PROGRAMME GRANT - TYROSINE KINASES: ONCOGENIC MODULATORS AND THERAPEUTIC TARGETS IN BREAST CANCER

Status	Finished
Effective start/end date	1/01/08 → 30/04/13

Development of mouse models of angiosarcoma driven by p53
Salter, D. M., Griffin, M., Muir, M., Teo, K., Culley, J., Smith, J. R., Gomez-Cuadrado, L., Matchett, K., Sims, A. H., Hayward, L., Henderson, N. C. & Brunton, V. G., 9 Jul 2019, In: Disease Models and Mechanisms. 12, dmm038612.
Research output: Contribution to journal › Article › peer-review

Open Access
File
Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer
Creedon, H., Balderstone, L. A., Muir, M., Balla, J., Gomez-cuadrado, L., Tracey, N., Loane, J., Klinowska, T., Muller, W. J. & Brunton, V. G., 1 Feb 2016, In: Disease Models and Mechanisms. 9, 2, p. 131-140
Research output: Contribution to journal › Article › peer-review

Open Access
File
Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer induced bone cell activity, bone remodelling, and osteolysis
Logan, J. G., Sophocleous, A., Marino, S., Muir, M., Brunton, V. G. & Idris, A. I., May 2013, In: Journal of Bone and Mineral Research. 28, 5, p. 1229-1242 14 p.
Research output: Contribution to journal › Article › peer-review

Project Details